Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Restasis

Phase 3Small molecule

Aurinia Pharmaceuticals

Restasis is one of 65 small molecule programs targeting Eye Disease. It is currently in Phase 3.

3

Indications

17

Total Trials

0

Active Trials

64

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Dry Eye SyndromeActive, not recruiting

Keratoconjunctivitis SiccaActive, not recruiting

Eye DiseasePhase 2

Active, not recruiting

Dry Eye SyndromePhase 3

Active, not recruiting

Keratoconjunctivitis SiccaPhase 2

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Alphagan

Bayer Aspirin

CF101

CCan-Fite BioPharma

Carboxymethylcellulose

Restasis

Aurinia Pharmaceuticals

Refresh Plus

Csa

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Cenegermin

DDompé Farmaceutici S.p.A

Diquafosol Tetrasodium

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dry Eye Syndrome6 trials

Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome

Completed·HHuons Co., Ltd.·Phase 2·NCT02917512·114 enrolled

Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

Completed·TTaejoon Pharmaceutical Co., Ltd.·Phase 3·NCT02461719·158 enrolled

Efficacy and Safety of HE10 for Dry Eye Syndrome

Completed·HHuons Co., Ltd.·Phase 3·NCT02492412·101 enrolled

Show 3 more trials

HU007 in Patients with Dry Eye Syndrome

Completed·HHuons Co., Ltd.·Phase 3·NCT05743764·328 enrolled

Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes

Completed·DDH Bio Co., Ltd.·Phase 3·NCT01804361·90 enrolled

Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

Completed·HHuons Co., Ltd.·Phase 3·NCT03461575·209 enrolled

Randomized2 trials

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Completed·OOphthalmic Consultants of Long Island·Phase 4·NCT00407043·5 enrolled

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Withdrawn·—·Phase 4·NCT02028312

Eye Disease2 trials

Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease

Completed·FFederal University of São Paulo·Phase 4·NCT02004067·100 enrolled

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Completed· Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals·Phase 2·NCT03597139·100 enrolled

Disease Progression1 trial

Topical Cyclosporine and Disease Progression

Completed·IInnovative Medical·Phase 4·NCT00567983·80 enrolled

Imaging1 trial

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

Unknown status·MMeir Medical Center·N/A·NCT03403023·40 enrolled

5 more indications

Graft Versus Host Disease1 trial

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Completed·UUniversity of Michigan·N/A·NCT01695668·75 enrolled

Keratoconjunctivitis sicca1 trial

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Completed·BBausch & Lomb Incorporated·Phase 2·NCT01817582·102 enrolled

MPA1 trial

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers

Completed·OOphRx Ltd.·Phase 1·NCT05184517·20 enrolled

Surgery1 trial

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

Completed·WWills Eye·N/A·NCT00405431·43 enrolled

Unspecified1 trial

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

Completed·BBoston Sight·Phase 1/2·NCT04918823·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Restasis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Restasis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Restasis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aurinia Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Aurinia Pharmaceuticals

Related News